reports
Man Group PLC : Form 8.3 - Tyman plc
Man Group PLC : Form 8.3 - Tyman plc FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Man Group PLC(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form...
Hitachi Energy to invest additional $1.5 billion to ramp up global tra...
Hitachi Energy to invest additional $1.5 billion to ramp up global transformer production by 2027 Capacity expansion will increase speed to market to meet accelerating global demand, address long-term customer investments and create over 4,000 jobs -- Investments span across Europe, the Americas, and Asia leveraging existing global footprint -- Around $180 million in a new state-of-the-art transformer factory in Finland, a key location for clean technology development for renewables and industrial electrification Zurich, April 23, 2024 (GLOBE NEWSWIRE) -- Hitachi Energy today reveal...
CorVel Announces New Integrations for Managed Care Services Enabling P...
CorVel Announces New Integrations for Managed Care Services Enabling Partners to Increase Connectivity and Create a Seamless Workflow Experience New integrations are propelled by technology that will create a best-in-class marketplace of services FORT WORTH, Texas, April 23, 2024 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL), a national provider of risk management solutions, is announcing upcoming innovations to its managed care service offerings. Over the past year, CorVel has invested substantially in advanced technologies, particularly Generative AI. As a result, CorVel is pl...
Bell Food Group AG: 1 director
A director at Bell Food Group AG sold 100 shares at 276.000CHF and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Close Brothers Group: 2 directors
A director at Close Brothers Group bought 6,500 shares at 446p and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Mestron Holdings Berhad: 2 directors
Two Directors at Mestron Holdings Berhad sold 8,000,000 shares at 0.250MYR. The significance rating of the trade was 44/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Manhattan Bridge Capital, Inc. Reports First Quarter Results for 2024
Manhattan Bridge Capital, Inc. Reports First Quarter Results for 2024 GREAT NECK, N.Y., April 23, 2024 (GLOBE NEWSWIRE) -- Manhattan Bridge Capital, Inc. (Nasdaq: ) announced today that its net income for the three months ended March 31, 2024 was approximately $1,476,000, or $0.13 per share (based on approximately 11.4 million weighted-average outstanding common shares), compared to approximately $1,260,000, or $0.11 per share (based on approximately 11.5 million weighted-average outstanding common shares) for the three months ended March 31, 2023, an increase of $21...
EQS-News: DER ACCUTOX ARM-002-IMPFSTOFF ZUR KREBSBEKÄMPFUNG FÜHRT ZU E...
EQS-News: Defence Therapeutics Inc. / Schlagwort(e): Sonstiges DER ACCUTOX ARM-002-IMPFSTOFF ZUR KREBSBEKÄMPFUNG FÜHRT ZU EINER HOCHWIRKSAMEN ANTIGENPRÄSENTATION 23.04.2024 / 13:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Vancouver, British Columbia, Kanada, den 23. April 2024 - Defence Therapeutics Inc. („Defence“ oder das „Unternehmen“), (CSE: DTC, OTCQB: DTCFF, Börse Frankfurt: DTC), ein kanadisches Biotech-Unternehmen, das neuartige immunonkologische Therapeutika und Technologien zur Arzneimittelverabreichung entwickelt, fr...
Lantronix to Participate in the 21st Annual Craig-Hallum Institutional...
Lantronix to Participate in the 21st Annual Craig-Hallum Institutional Investor Conference on May 29, 2024 IRVINE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: LTRX), a global provider of compute and connectivity IoT solutions, today announced that Lantronix CEO Saleel Awsare and CFO Jeremy Whitaker will participate in one-on-one meetings with investors at the 21st Annual Craig-Hallum Institutional Investor Conference to be held on May 29, 2024, at the Depot Renaissance Hotel in Minneapolis. Interested investors should contact Lantronix CFO Jeremy Whitaker at for one-on-one meet...
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Dis...
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results WALTHAM, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2024 financial results on Tuesday, May 7, 2024, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call . A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of the compan...
Mezzion Pharma Co Ltd: 1 director
A director at Mezzion Pharma Co Ltd maiden bought 750 shares at 35,600.000KRW and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...
Omega Therapeutics to Present New Preclinical Data on Epigenomic Upreg...
Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced it will present a poster at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place in Baltimore, MD, May 7 – 11, 2024. The poster will feature new preclinical data that dem...
Theriva™ Biologics anuncia datos de primera línea positivos del ensayo...
Theriva™ Biologics anuncia datos de primera línea positivos del ensayo de fase 1 patrocinado por investigadores de VCN-01 por vía intravítrea en pacientes pediátricos con retinoblastoma refractario –El Comité de vigilancia del estudio ha determinado que el ensayo de fase 1 en colaboración con el Hospital Infantil Sant Joan de Déu Barcelona (SJD) tiene un resultado positivo– –La seguridad y los resultados clínicos respaldan el potencial terapéutico del VCN-01 en el retinoblastoma y subrayan el potencial del VCN-01 para su uso en diversas indicaciones oncológicas– ROCKVILLE, Maryland, A...
GXO Renews Agreement with Mars
GXO Renews Agreement with Mars 15-year partnership enhancing supply chain operations with automated solutions PARIS, France, April 23, 2024 (GLOBE NEWSWIRE) -- (NYSE: GXO), the world’s largest pure-play contract logistics provider, announced today that it has renewed its contract with major consumer packaged goods company, Mars in France, a partnership that started 15 years ago. GXO manages storage, distribution, returns and value added-services for a number of Mars brands across its Snacking and Food & Nutrition segments. “We are delighted to expand our partnership with Mars in...
Option Care Health Announces Financial Results for the First Quarter E...
Option Care Health Announces Financial Results for the First Quarter Ended March 31, 2024 BANNOCKBURN, Ill., April 23, 2024 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results and Highlights Net revenue of $1,146.1 million, up 12.8% compared to $1,015.8 million in the first quarter of 2023Gross profit of $238.5 million, or 20.8% of net rev...
Lithium Ionic Expands Newly Discovered Zone at Salinas; Drills 1.53% L...
Lithium Ionic Expands Newly Discovered Zone at Salinas; Drills 1.53% Li2O over 15m, incl. 2.31% Li2O over 8m; 1.15% Li2O over 19m, incl. 1.67% Li2O over 10m, and 1.32% Li2O over 14m Excellent follow-up drill results from high-grade discovery holes at the “Noé” target announced in , including: 1.53% Li2O over 15m, incl. 2.31% Li2O over 8m1.15% Li2O over 19m, incl. 1.67% Li2O over 10m1.32% Li2O over 14m, incl. 2.16% Li2O over 7m The Noé target, located ~1.5km north of the mineral resource area, was not included in the NI 43-101 estimate announced on Salinas currently hosts a 14.76Mt lithium d...
Plug Continues to Make Substantial Advancement in Hydrogen Generation ...
Plug Continues to Make Substantial Advancement in Hydrogen Generation Buildout Having already achieved nameplate capacity at Georgia and Tennessee with Louisiana on track to achieve mechanical completion by end of Q3 2024 Recalibrated hydrogen pricing continues to make solid progress, underscoring strategic nature of Plug’s customer relationships These initiatives are in line with the company’s previously articulated goals of margin expansion and focus on cash burn reduction LATHAM, N.Y., April 23, 2024 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in ...
First Commonwealth Announces First Quarter 2024 Earnings; Increases Qu...
First Commonwealth Announces First Quarter 2024 Earnings; Increases Quarterly Dividend INDIANA, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- First Commonwealth Financial Corporation (NYSE: FCF) today announced financial results for the first quarter of 2024. Financial Summary (dollars in thousands,For the Three Months Endedexcept per share data)March 31, December 31, March 31, 2024 2023 2023 Reported Results Net income$37,549 $44,827 $30,224 Diluted earnings per share$0.37 $0.44 $0.30 Return on average assets 1.31% 1.56% 1.17%Return on average equity 11.40% 14.11% 10.56% ...
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medici...
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit PHILADELPHIA, April 23, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a virtual fireside chat and panel at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, details of the presentations are as follows: Fireside Chat...
Revive Therapeutics Announces Type C Meeting Request Granted by FDA fo...
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID TORONTO, April 23, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today that the U.S. Food & Drug Administration (“FDA”) has granted the Company’s Type C meeting request for the evaluation of a proposed clinical s...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.